Clinical Efficacy of MAGNEX®

CEFOPERAZONE/SULBACTAM is the only agent versus selected comparators to  have an average resistance rate of lower than 40% against common gram-negative bacteria in AECOPD lower respiratory tract infections2

CEFOPERAZONE/SULBACTAM at a 2:1 ratio is appropriate to treat Acinetobacter species and at a 1:1 or a 1:2 ratio could treat multidrug-resistant organisms3

CEFOPERAZONE/SULBACTAM (1:1 or 1:2) has greater in vitro activity against most multidrug-resistant  organisms (ESBL- and AmpC-producing Enterobacteriaceae and carbapenem-resistant A. baumannii,  except for carbapenem-resistant P. aeruginosa)3
 

CEFOPERAZONE/SULBACTAM: A valuable antimicrobial agent with wide  antimicrobial spectrum, notable effect, few side effects, especially in patients  with severe nosocomial lower respiratory tract infections4

The total efficacy rate of cefoperazone sodium and sulbactam sodium was 86.7%, the bacterial  eradication rate was 93.1% and no serious adverse reactions were found4

CEFOPERAZONE/SULBACTAM is more efficient in the treatment of uraemic  patients with pulmonary infection than cefoperazone, which does not increase  adverse reactions and has a high safety profile5

The efficiency rate of the treatment group was 83.3% and the bacterial clearance rate was 92.86%; in  the control group, the overall efficiency rate was 63.3%, the bacterial clearance rate was 72.41% and  the curative effect of the treatment group was better than the control group5

CEFOPERAZONE/SULBACTAM is recommended as an effective and  well-tolerated  antibiotic for treating IAIs: Meta-analysis outcomes6

Overall, the clinical efficacy rate of CEFOPERAZONE/SULBACTAM and comparators was 87.7% and  81.7%, respectively, and CEFOPERAZONE/SULBACTAM was associated with a higher clinical efficacy  rate than that of the comparator (OR: 1.98; 95% CI: 1.31-3.00; I2 = 36%; P = 0.10)6

Study Design: In this systematic review and meta-analysis, 12 studies involving 1674 patients were included. The PubMed,  Cochrane, Web of Science, Ovid MEDLINE and CNKI databases were searched for relevant articles up to  25 November 2020. The primary outcome was clinical efficacy rate, and the secondary outcomes were microbiologic eradication rate,  mortality rate and AE risk.

CEFOPERAZONE/SULBACTAM was associated with a higher microbiologic  eradication rate than that of the comparator in patients with IAI: Meta-  analysis outcomes6

CEFOPERAZONE/SULBACTAM was associated with a higher microbiologic eradication rate than  that of the comparator (OR: 2.54; 95% CI: 1.72-3.76; I2 = 0)6

Study Design: In this systematic review and meta-analysis, 12 studies involving 1674 patients were included. The PubMed,  Cochrane, Web of Science, Ovid MEDLINE and CNKI databases were searched for relevant articles up to 25 November 2020.  The primary outcome was clinical efficacy rate, and the secondary outcomes were microbiologic eradication rate, mortality  rate and AE risk.

AE: adverse event; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; CI: confidence interval; CNKI: china knowledge resource  integrated database; ESBL: extended-spectrum beta-lactamase; IAI: intra-abdominal infection; OR: odds ratio.

References: 1. MAGNEX®/MAGNEX® FORTE Injection. LPDMGX042020. 2. Hu F, Zhu D, Wang F, et al. Report of CHINET antimicrobial resistance  surveillance program in 2015. Chin J Infect Chemother. 2016;16(6):685-694. 3. Ku YH, Yu WL. Cefoperazone/sulbactam: New  composites against multiresistant gram negative bacteria?. Infection, Genetics and Evolution. 2021 Jan 5:104707. 4. ZHOU Gan ZUO  Wenjie PAN Sujie. China Modern Medicine. 2012;23:117-118. 5. XIE Quan-kun, LIU Shu-zhen. China Health Industry. 2016;6:55-57. 6. Lan SH, Chao  CM, Chang SP, et al. Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and  Meta-Analysis [published online ahead of print, 2021 Feb 23]. Surg Infect (Larchmt). 2021;10.1089/sur.2020.468.
 

PP-MGX-IND-0397. 09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of MAGNEX®  
For the use only of registered medical practitioner, or a hospital or a laboratory.